Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, LUMC Co-developing Tumor Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dutch molecular diagnostics shop Kreatech Diagnostics announced today a co-development deal with Leiden University Medical Center directed at fluorescent in situ hybridization probes for genetic targets in bone and soft tissue tumors.

Biomarkers resulting from research conducted at LUMC will be used to design and commercialize diagnostic tests for the differential diagnosis of tumors and as companion diagnostics, Kreatech said. LUMC will validate the probes and Kreatech will manufacture and commercialize them.

Further terms of the deal were not disclosed.

The first three probes, which will focus on sarcoma diagnostics, are expected to be launched this year. The two partners also intend to develop a range of FISH probes for the pathology field.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.